FDA Turmoil: Indian American Scientist Resigns Amid Regulatory Clashes

indica News Bureau- 

A clash between regulatory rigor and the pharmaceutical industry has resulted in the resignation of an Indian American scientist who headed the FDA’s vaccine and therapy approval wing. The scientist was at the center of several controversies over his decisions to tighten certain regulations.

Indian American scientist Prasad had attempted to impose stricter clinical trial standards—a move that triggered significant pushback from major drug manufacturers. His departure, the second one in a year, signals a period of deep instability within the government’s most critical public health oversight body.

His departure for the second time from the post of director of the Food and Drug Administration’s Centre for Biologics Evaluation and Research within a year was announced by the agency’s head, Marty Makary.

Prasad had quit his job in July, less than two months after taking the directorship, due to criticism from the extreme right regarding his past remarks in support of Democrats. But he was brought back in August by Health Secretary Robert F Kennedy Jr, with whom he shared some scepticism of the medical establishment and the pharmaceutical industry.

Makary said on X that Prasad, who “got a tremendous amount accomplished” during his tenure, will return to the University of California, San Francisco, where he is a professor. “Under his leadership, his centre hit a record number of approvals” of medications, he added.

Although he loosened some of the trial requirements for therapies, such as requiring only one major study instead of two, the types of trials he demanded created run-ins with pharmaceutical corporations.

A recent one was with Moderna when he blocked its application for releasing a flu vaccine, questioning its trials. The company and others in the pharmaceutical industry fought back, and Makary overruled Prasad.

Another controversy was over his refusal to allow an application from the Dutch company UniQure for a drug for Huntington’s Disease, an ailment that affects the brain.

While he was in academia, he criticised some of the regulations and procedures introduced by the administration of former President Joe Biden during the COVID pandemic. That and his criticism of the FDA and the pharmaceutical industry caught the attention of Kennedy.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source